Raltegravir and Atazanavir Dosing Strategy Study

PHASE3CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
HIV Infection
Interventions
DRUG

atazanavir plus raltegravir

atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks

DRUG

atazanavir plus raltegravir

atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks

Trial Locations (2)

2010

Holdsworth House Medical Practice, Sydney

St Vincent's Hospital, Sydney

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kirby Institute

OTHER_GOV